MEGAN THOMPSON: Open Payments
NPI 1851992549 · NEW ALBANY, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$620 in 35 payments from 12 companies in 2025. Trend: 2023 $135 · 2024 $276 · 2025 $620
Food & beverage: $620
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $112 |
| Lilly USA, LLC | 5 | $79 |
| Novo Nordisk Inc | 5 | $79 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $59 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| Esperion Therapeutics, Inc. | 3 | $51 |
| Amgen Inc. | 3 | $45 |
| ABBVIE INC. | 2 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38 |
| GlaxoSmithKline, LLC. | 1 | $22 |
Products named: JARDIANCE, CAPLYTA, FARXIGA, GEMTESA, NEXLETOL, Wegovy, QULIPTA, BREZTRI.
Industry payments across MS — which companies pay providers there.
